| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1591 | 2022 |
| Mpox in people with advanced HIV infection: a global case series O Mitjà, A Alemany, M Marks, JIL Mora, JC Rodríguez-Aldama, MST Silva, ... The Lancet 401 (10380), 939-949, 2023 | 206 | 2023 |
| Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial JJ Feld, C Kandel, MJ Biondi, RA Kozak, MA Zahoor, C Lemieux, ... The Lancet Respiratory Medicine 9 (5), 498-510, 2021 | 204 | 2021 |
| Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’byrne, R Thomas, J Kille, ... Cmaj 189 (47), E1448-E1458, 2017 | 197 | 2017 |
| Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act RW Burgoyne, DHS Tan Journal of antimicrobial chemotherapy 61 (3), 469-473, 2008 | 178 | 2008 |
| Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act RW Burgoyne, DHS Tan Journal of antimicrobial chemotherapy 61 (3), 469-473, 2008 | 178 | 2008 |
| “Maybe if I stop the drugs, then maybe they’d care?”—hospital care experiences of people who use drugs S Chan Carusone, A Guta, S Robinson, DH Tan, C Cooper, B O’Leary, ... Harm Reduction Journal 16, 1-10, 2019 | 163 | 2019 |
| Multidrug-resistant HIV-1 infection despite preexposure prophylaxis DC Knox, PL Anderson, PR Harrigan, DHS Tan New England Journal of Medicine 376 (5), 501-502, 2017 | 137 | 2017 |
| Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier, YA Cavayas, ... Cmaj 194 (7), E242-E251, 2022 | 136 | 2022 |
| The pre-exposure prophylaxis-stigma paradox: learning from Canada's first wave of PrEP users D Grace, J Jollimore, P MacPherson, MJP Strang, DHS Tan AIDS patient care and STDs 32 (1), 24-30, 2018 | 136 | 2018 |
| Use of an HIV‐risk screening tool to identify optimal candidates for PrEP scale‐up among men who have sex with men in Toronto, Canada: disconnect between objective and … J Wilton, T Kain, S Fowler, TA Hart, T Grennan, J Maxwell, DHS Tan Journal of the International AIDS Society 19 (1), 20777, 2016 | 113 | 2016 |
| Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study C Orkin, S Oka, P Philibert, C Brinson, A Bassa, D Gusev, O Degen, ... The Lancet HIV 8 (4), e185-e196, 2021 | 107 | 2021 |
| Preparing for PrEP: perceptions and readiness of Canadian physicians for the implementation of HIV pre-exposure prophylaxis M Sharma, J Wilton, H Senn, S Fowler, DHS Tan PLoS One 9 (8), e105283, 2014 | 85 | 2014 |
| High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada AN Burchell, VG Allen, SL Gardner, V Moravan, DHS Tan, R Grewal, ... BMC infectious diseases 15, 1-9, 2015 | 83 | 2015 |
| Disseminated fungal infection in a renal transplant recipient involving Macrophomina phaseolina and Scytalidium dimidiatum: case report and review of taxonomic … DHS Tan, L Sigler, CFC Gibas, IW Fong Medical Mycology 46 (3), 285-292, 2008 | 80 | 2008 |
| Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase … C Orkin, EB Morell, DHS Tan, H Katner, HJ Stellbrink, E Belonosova, ... The Lancet HIV 8 (11), e668-e678, 2021 | 75 | 2021 |
| Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines EAF Simoes, DHS Tan, A Ohlsson, V Sales, EEL Wang Vaccine 20 (5-6), 954-960, 2001 | 75 | 2001 |
| Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada M Leonardi, E Lee, DHS Tan International journal of STD & AIDS 22 (12), 738-741, 2011 | 69 | 2011 |
| Illicit drug use while admitted to hospital: Patient and health care provider perspectives C Strike, S Robinson, A Guta, DH Tan, B O'Leary, C Cooper, R Upshur, ... Plos one 15 (3), e0229713, 2020 | 68 | 2020 |
| Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review J Wilton, H Senn, M Sharma, DHS Tan HIV/AIDS-Research and Palliative Care, 125-136, 2015 | 68 | 2015 |
